6 No source found (not proven false)
A clinical trial evaluating a GDF15-blocking antibody in heart failure was terminated because participants receiving the drug developed more heart failure and adverse events.
"recently there's another trial, uh large-scale trial for heart failure, uh that looked at this using this antibody to block... Turns out uh many more people developed uh heart failure and like adverse events uh under the drug. So they stopped the trial where you block GDF-15." (said at 1:40:51)
No published clinical trial or trial termination record was identified evaluating a GDF15-blocking antibody in heart failure where the study was stopped due to increased heart failure or adverse events in the treatment arm. GDF15 is widely recognized as a prognostic biomarker elevated in cardiovascular disease and heart failure, and GDF15-neutralizing monoclonal antibodies (such as ponsegromab or AZD8853) have entered clinical trials primarily for cancer cachexia, solid tumors, and related indications rather than completed large-scale therapeutic trials in heart failure showing termination for excess heart failure events.
There are approximately 100,000 hairs on the human head.
"Like you have every hair on your body, there's about 100,000 hairs on your head, uh every hair has the same genome." (said at 1:43:46)
No published records were fetched within the search query limit to directly verify the specific figure from indexed literature abstracts in this session. In general anatomical and dermatological literature, the average human scalp is widely documented to possess approximately 80,000 to 120,000 (commonly cited as ~100,000) hair follicles/hairs, making the statement consistent with standard textbook estimates, though unverified here against specific fetched PubMed abstracts.
During sleep, reduced body temperature and heart rate decrease metabolic energy expenditure by 10% to 15%.
"Most people know when you sleep your heart rate goes down and a bunch of your body temperature goes down, and uh that uh allows us to go, um, you know, to to stay alive with 10-15% lower energy expenditure. And that they're different between different people, but you know 10-15% is kind of a an average of how much energy you're saving by sleeping." (said at 1:57:56)
A literature search using PubMed and Europe PMC within the allowed search budget did not retrieve a study explicitly confirming or refuting the exact 10% to 15% reduction in metabolic energy expenditure during sleep resulting from decreased body temperature and heart rate. While physiological decreases in metabolic rate, heart rate, and core body temperature during sleep are well-documented phenomena, the specific quantitative estimate stated could not be verified from the fetched records.
Both myocardial contraction (systole) and myocardial relaxation (diastole) require active energy consumption.
"Every time the heart contracts, right, systole, diastole, both contraction, relaxation cost energy." (said at 2:02:00)
Although it is an established textbook physiological mechanism that both myocardial contraction (myosin ATPase-driven cross-bridge cycling) and myocardial relaxation (active calcium reuptake into the sarcoplasmic reticulum via SERCA2a and detachment of actin-myosin cross-bridges) consume ATP, no relevant full abstracts were successfully fetched within the search limit to verify and cite the specific literature directly.
Lifespan in people with genetic mitochondrial diseases is decreased by about 30 years.
"And lifespan in those people is decreased by about three decades." (said at 2:10:45)
No publication establishing a generalized, cross-disease reduction in lifespan of 'about three decades' (30 years) across all genetic mitochondrial diseases was located in the searched literature. Genetic mitochondrial diseases represent a highly heterogeneous group of conditions resulting from nuclear or mitochondrial DNA mutations; while some (such as infantile Leigh syndrome) result in severe early mortality and others (such as m.3243A>G-related MELAS or POLG-related disorders) often lead to premature mortality in mid-adulthood, lifespan varies widely by genotype, heteroplasmy, and clinical phenotype. This verdict does not prove the statement false, but the specific aggregate estimate could not be independently verified.
Jan Baszucki's son with bipolar disorder experienced mood stabilization, cessation of mania and depression cycling, and improved sleep within weeks of adopting a ketogenic diet.
"The Baszucki Group is a family foundation whose son was diagnosed with bipolar disease and tried all sorts of treatments and drugs that didn't work very well or actually made things worse... And then finally, they came across a psychiatrist who was using the ketogenic diet as a treatment. And so he went on a ketogenic diet, and Jan Baszucki, the mom, said, like, "I had my son back." Like, within a few weeks, his mood got stabilized, he was able to sleep, and he stopped kind of cycling between mania and major depression." (said at 1:58:16)
While the story of Jan and David Baszucki's son (Matt Baszucki) achieving remission from bipolar disorder after adopting a ketogenic diet under Dr. Christopher Palmer is widely documented in public media, interviews, and philanthropic materials of the Baszucki Group, no formal, peer-reviewed clinical case report of this specific named patient was located in the published medical literature. Published literature on ketogenic diets in bipolar disorder is currently limited to small pilot trials (e.g., PMID 39995103) and unrelated individual case reports/series (e.g., PMID 23030231, PMID 37098202). Per scientific verification standards for individual patient narratives, the specific clinical details of this private case cannot be independently verified against indexed peer-reviewed case literature.
- context: Ketogenic diet in therapy of bipolar affective disorder - case report and literature revie… (Psychiatria polska 2022) · cited 30x in the literature
"In the presented case study of a male patient, thanks to the introduction of the ketogenic diet, full remission of the disease was achieved, doses of lamotrigine were reduced and quetiapine was completely discontinued." (abstract, results, passage verified)
pubmedfull study (doi) - context: A pilot study of a ketogenic diet in bipolar disorder: clinical, metabolic and magnetic re… (BJPsych open 2025) · cited 32x in the literature
"Preliminary evidence suggests that a ketogenic diet may be effective for bipolar disorder... In participants providing reliable daily ecological momentary assessment data ( n = 14), there was a positive correlation between daily ketone levels and self-rated mood ( r = 0.21, P < 0.001) and energy ( r = 0.19 P < 0.001), and an inverse correlation between ketone levels and both impulsivity ( r = -0.30, P < 0.001) and anxiety ( r = -0.19, P < 0.001)." (abstract, results)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.